Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 903576-44-3
2. Ciproxidine
3. Bf 2649
4. Pitolisant Hcl
5. Pitolisant (hydrochloride)
6. Bf 2649 Hydrochloride
7. Yv33ch63hi
8. Pitolisant Hydrochloride [usan]
9. 1-(3-(3-(4-chlorophenyl)propoxy)propyl)piperidine Hydrochloride
10. Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-, Hydrochloride
11. 903576-44-3 (hcl)
12. Wakix (tn)
13. Pitolisant Hydrochloride (usan)
14. 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine Hydrochloride
15. 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine Hydrochloride
16. Piperidine, 1-(3-(3-(4-chlorophenyl)propoxy)propyl)-, Hydrochloride
17. Bf 2.649
18. Unii-yv33ch63hi
19. Schembl4591893
20. Bf-2649 Hydrochloride
21. Chembl4164059
22. Dtxsid50238098
23. Pitolisant;ciproxidine; Bf2649
24. Amy23423
25. Bcp16427
26. Ex-a1420
27. Hy-12199b
28. Pitolisant Hydrochloride [mi]
29. S5926
30. Akos024457784
31. Cs-1501
32. Sb17036
33. Pitolisant Hydrochloride [who-dd]
34. Ac-36017
35. As-72196
36. A3727
37. Pitolisant Hydrochloride [orange Book]
38. C77058
39. D11490
40. A900088
41. Q27895485
42. 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride
43. 1-(3-(3-(4-chlorophenyl)propoxy)propyl)piperidine Monohydrochloride
44. Piperidine, 1-(3-(3-(4-chlorophenyl)propoxy)propyl)-, Hydrochloride (1:1)
| Molecular Weight | 332.3 g/mol |
|---|---|
| Molecular Formula | C17H27Cl2NO |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 8 |
| Exact Mass | 331.1469699 g/mol |
| Monoisotopic Mass | 331.1469699 g/mol |
| Topological Polar Surface Area | 12.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 235 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39721
Submission : 2024-04-01
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-31
Pay. Date : 2023-03-15
DMF Number : 36859
Submission : 2022-03-01
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2023-05-19
Pay. Date : 2023-03-21
DMF Number : 38174
Submission : 2023-03-30
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2023-07-28
Pay. Date : 2023-07-06
DMF Number : 37753
Submission : 2022-12-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-06-22
Pay. Date : 2023-04-21
DMF Number : 38307
Submission : 2023-05-09
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2024-08-22
Pay. Date : 2024-07-25
DMF Number : 39126
Submission : 2023-12-05
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-05-17
Pay. Date : 2023-04-25
DMF Number : 38131
Submission : 2023-03-27
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
HBS-301 (Pitolisant) is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of idiopathic hypersomnia.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: HBS-301
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Details : HBS-301 (Pitolisant) is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of idiopathic hypersomnia.
Product Name : HBS-301
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pitolisant HCl, a miscellaneous product targeting the H3 receptor, shows promise in treating narcolepsy.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: Wakix-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Gets Tentative Approval from US FDA for Pitolisant Tablets
Details : Pitolisant HCl, a miscellaneous product targeting the H3 receptor, shows promise in treating narcolepsy.
Product Name : Wakix-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pitolisant HCl is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Prader-Willi Syndrome.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Pitolisant in Participants With Prader-Willi Syndrome
Details : Pitolisant HCl is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Prader-Willi Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
HBS-201 (Pitolisant HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Narcolepsy.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: HBS-201
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HBS-201 (Pitolisant Delayed-release)
Details : HBS-201 (Pitolisant HCl) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Narcolepsy.
Product Name : HBS-201
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Wakix (pitolisant) is an oral H3 receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of idiopathic hypersomnia.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Harmony Provides Update on the Status of the sNDA for Pitolisant in Idiopathic Hypersomnia
Details : Wakix (pitolisant) is an oral H3 receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of idiopathic hypersomnia.
Product Name : Wakix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Wakix (pitolisant) is an oral H3 receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of narcolepsy in pediatric patients 6 years of age and older.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Sleep Brand Name: Wakix
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HARMONY BIOSCIENCES Receives FDA Approval for WAKIX® in Pediatric Narcolepsy
Details : Wakix (pitolisant) is an oral H3 receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of narcolepsy in pediatric patients 6 years of age and older.
Product Name : Wakix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pitolisant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prader-Willi Syndrome.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Details : Pitolisant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prader-Willi Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Harmony Biosciences Begins Global Phase 3 Trial of Pitolisant for Prader-Willi Syndrome
Details : Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Product Name : Wakix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Harmony Receives Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome
Details : Wakix (pitolisant) is an oral histamine-3 (H3) receptor antagonist/inverse agonist, small molecule drug. It is being evaluated for the treatment of Prader-Willi syndrome.
Product Name : Wakix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Wakix (pitolisant HCl) is a 5-HT3 receptor Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of adult patients with myotonic dystrophy type 1.
Lead Product(s): Pitolisant Hydrochloride,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Wakix
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitolisant Hydrochloride,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Wakix (pitolisant HCl) is a 5-HT3 receptor Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of adult patients with myotonic dystrophy type 1.
Product Name : Wakix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 6282-88-8
End Use API : Pitolisant Hydrochloride
About The Company : Operational since 2024, ApiSyn Healthcare Pvt. Ltd. is a rapidly growing cGMP manufacturer and CDMO specializing in APIs, intermediates, peptides, and amino aci...
3-(4-chlorophenyl)propyl methanesulfonate
CAS Number : 61440-60-6
End Use API : Pitolisant Hydrochloride
About The Company : Operational since 2024, ApiSyn Healthcare Pvt. Ltd. is a rapidly growing cGMP manufacturer and CDMO specializing in APIs, intermediates, peptides, and amino aci...
3-(4-chlorophenyl) propionic acid
CAS Number : 2019-34-3
End Use API : Pitolisant Hydrochloride
About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Company : Harmony Bioscie
Pitolisant HCl
Drug Cost (USD) : 101,374,313
Year : 2023
Prescribers : 1235
Prescriptions : 8703

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Harmony Bioscie
Pitolisant HCl
Drug Cost (USD) : 65,551,787
Year : 2022
Prescribers : 940
Prescriptions : 6217

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Harmony Bioscie
Pitolisant HCl
Drug Cost (USD) : 55,827,154
Year : 2021
Prescribers : 825
Prescriptions : 5502

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Harmony Bioscie
Pitolisant HCl
Drug Cost (USD) : 31,542,408
Year : 2020
Prescribers : 657
Prescriptions : 3671

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Harmony Bioscie
Pitolisant HCl
Drug Cost (USD) : 1,200,834
Year : 2019
Prescribers : 89
Prescriptions : 208

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
18 Sep 2025
Reply
01 May 2025
Reply
24 Aug 2024
Reply
23 Jan 2023
Reply
06 Sep 2022
Reply
05 Jul 2022
Reply
10 Jan 2020
Reply
03 Oct 2019
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Pitolisant Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Pitolisant Hydrochloride manufacturer or Pitolisant Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pitolisant Hydrochloride manufacturer or Pitolisant Hydrochloride supplier.
A Pitolisant Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pitolisant Hydrochloride, including repackagers and relabelers. The FDA regulates Pitolisant Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pitolisant Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pitolisant Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Pitolisant Hydrochloride supplier is an individual or a company that provides Pitolisant Hydrochloride active pharmaceutical ingredient (API) or Pitolisant Hydrochloride finished formulations upon request. The Pitolisant Hydrochloride suppliers may include Pitolisant Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Pitolisant Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Pitolisant Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Pitolisant Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Pitolisant Hydrochloride DMFs exist exist since differing nations have different regulations, such as Pitolisant Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pitolisant Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Pitolisant Hydrochloride USDMF includes data on Pitolisant Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pitolisant Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pitolisant Hydrochloride suppliers with USDMF on PharmaCompass.
A Pitolisant Hydrochloride written confirmation (Pitolisant Hydrochloride WC) is an official document issued by a regulatory agency to a Pitolisant Hydrochloride manufacturer, verifying that the manufacturing facility of a Pitolisant Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pitolisant Hydrochloride APIs or Pitolisant Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Pitolisant Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Pitolisant Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pitolisant Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pitolisant Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pitolisant Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pitolisant Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pitolisant Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pitolisant Hydrochloride suppliers with NDC on PharmaCompass.
Pitolisant Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pitolisant Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Pitolisant Hydrochloride GMP manufacturer or Pitolisant Hydrochloride GMP API supplier for your needs.
A Pitolisant Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Pitolisant Hydrochloride's compliance with Pitolisant Hydrochloride specifications and serves as a tool for batch-level quality control.
Pitolisant Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Pitolisant Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pitolisant Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Pitolisant Hydrochloride EP), Pitolisant Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pitolisant Hydrochloride USP).